The Pharma Data
DECEMBER 14, 2020
ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.
Scienmag
SEPTEMBER 15, 2020
15, 2020 — Initial findings reported by the Arizona COVID-19 Genomics Union (ACGU) suggest that following Arizona’s first reported case of COVID-19 in late January, the state experienced no cases that went undetected […]. — Sept.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 21, 2024
As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.
The Pharma Data
DECEMBER 13, 2020
Food and Drug Administration (FDA) approved a first-of-its-kind intentional genomic alteration (IGA) in a line of domestic pigs, referred to as GalSafe pigs, which may be used for food or human therapeutics. SILVER SPRING, Md. , 14, 2020 /PRNewswire/ — Today, the U.S. In the U.S., The FDA, an agency within the U.S.
Delveinsight
AUGUST 27, 2020
Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. Targeted drug combo attacks breast cancer brain metastases in mice.
pharmaphorum
OCTOBER 1, 2021
It also won a £113 million contract to provide rapid saliva-based COVID-19 testing services to the NHS, although that was ended early by the UK government in the summer as demand fell due to vaccinations. Chief technology officer Clive Brown is also sitting on a £10 million stake.
XTalks
NOVEMBER 30, 2023
These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress.
Expert insights. Personalized for you.
52 
Let's personalize your content